Targeting myeloperoxidase to reduce neuroinflammation in X-linked dystonia parkinsonism

Tiziana Petrozziello,Negin J. Motlagh,Ranee Z.B. Monsanto,Dan Lei,Micaela G. Murcar,Ellen B. Penney,D. Cristopher Bragg,Cara Fernandez-Cerado,G. Paul Legarda,Michelle Sy,Edwin Munoz,Mark C. Ang,Cid Czarina E. Diesta,Can Zhang,Rudolph E. Tanzi,Irfan A. Qureshi,John W. Chen,Ghazaleh Sadri-Vakili

DOI: https://doi.org/10.1101/2024.06.25.24309481

2024-06-25

Abstract:Although the genetic locus of X-linked dystonia parkinsonism (XDP), a neurodegenerative disease endemic in the Philippines, is well-characterized, the exact molecular mechanisms leading to neuronal loss are not yet fully understood. Recently, we demonstrated a significant increase in astrogliosis and microgliosis together with an increase in myeloperoxidase (MPO) levels in XDP post-mortem prefrontal cortex (PFC), suggesting a role for neuroinflammation in XDP pathogenesis. Here, we demonstrated a significant increase in MPO activity in XDP PFC using a novel specific MPO-activatable fluorescent agent (MAFA). Additionally, we demonstrated a significant increase in reactive oxygen species (ROS) in XDP-derived fibroblasts as well as in SH-SY5Y cells treated with post-mortem XDP PFC, further supporting a role for MPO in XDP. To determine whether increases in MPO activity were linked to increases in ROS, MPO content was immuno-depleted from XDP PFC [MPO(-)], which resulted in a significant decrease in ROS in SH-SY5Y cells. Consistently, the treatment with verdiperstat, a potent and selective MPO inhibitor, significantly decreased ROS in both XDP-derived fibroblasts and XDP PFC-treated SH-SY5Y cells. Collectively, our results suggest that MPO inhibition mitigates oxidative stress and may provide a novel therapeutic strategy for XDP treatment.

Neurology